Drug Trial Radar · NCT03488485
Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model
Last checked: Nov 19, 2026Latest source record: Jun 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50,000
Planned (sponsor's estimate)
Start
Jun 18, 2016
Primary completion
Dec 2020
Study completion Dec 2020
Sponsor
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Directorate of Health and Family Welfare, Punjab
- First posted
- Apr 5, 2018
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background and Aims: The prevalence of hepatitis C virus infection (HCV) infection in Punjab, India is 3.29%, with an estimated burden of around 650,000 viremic chronic HCV (CHC) patients. The Mukh Mantri Punjab Hepatitis C Relief Fund (MMPHCRF) was launched in June 2016 to provide free treatment to all CHC aiming to eliminate HCV from Punjab. The study assessed the feasibility of decentralized care and efficacy and safety of 12 or 24 weeks of sofosbuvir (SOF) + ledipasvir (LDV) or SOF + daclatasvir (DCV) ± ribavirin (RBV) in the treatment of CHC patients in a public health care setting.
Conditions
- Chronic Hepatitis c
Interventions
Direct Acting AntiviralsDrug
DAAs given in patients with viremic chronic hepatitis C
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained Virological ResponseTime frame: Up to study completion ( average 12 -24 weeks after therapy)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Post Graduate Institute of Medical Education and Research
Chandigarh, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.